American Oncology Network, Inc. Class A Common Stock
AONC
AONC was delisted on the 7th of June, 2024.
6 hedge funds and large institutions have $349K invested in American Oncology Network, Inc. Class A Common Stock in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
146% more capital invested
Capital invested by funds: $142K → $349K (+$207K)
100% more funds holding
Funds holding: 3 → 6 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Applied Capital
Little Rock,
Arkansas
|
+$243K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.8K |
| 3 |
Barclays
London,
United Kingdom
|
+$246 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$71 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$23.6K |
| 2 |
JP Morgan Chase
New York
|
-$2.08K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Applied Capital
Little Rock,
Arkansas
| $221K | +$243K | +37,499 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $127K | +$62.8K | +9,683 | +78% |
|
|
3
Barclays
London,
United Kingdom
| $224 | +$246 | +38 | New |
|
|
4
Wells Fargo
San Francisco,
California
| $65 | +$71 | +11 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $18 | +$19 | +3 | New |
|
|
6
JP Morgan Chase
New York
| $12 | -$2.08K | -321 | -99% |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$23.6K | -2,540 | Closed |
|
AONC Hedge Fund Activity: Q4 2023 in Review
6 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in American Oncology Network, Inc. Class A Common Stock (AONC) for Q4 2023, worth a combined $349K — up 146% from $142K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AONC positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Applied Capital, opening a new position worth an estimated $243K. The largest seller was UBS Group, exiting entirely with an estimated $23.6K sold.
- 6 institutional investors held American Oncology Network, Inc. Class A Common Stock (AONC) as of Q4 2023, up from 3 in Q3 2023.
- Funds reported $349K of American Oncology Network, Inc. Class A Common Stock stock for Q4 2023, up 146% quarter-over-quarter.
- 4 funds opened new American Oncology Network, Inc. Class A Common Stock positions in Q4 2023 and 1 closed out, a net change of +3 holders.
- The largest American Oncology Network, Inc. Class A Common Stock buyer in Q4 2023 was Applied Capital, an estimated $243K added.
- The largest American Oncology Network, Inc. Class A Common Stock seller in Q4 2023 was UBS Group, an estimated $23.6K sold.
Based on aggregated 13F filings for Q4 2023.